<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01364259</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-14896</org_study_id>
    <secondary_id>SU-05252011-7806</secondary_id>
    <nct_id>NCT01364259</nct_id>
  </id_info>
  <brief_title>A Study of Amifostine for Prevention of Facial Numbness in Radiosurgery Treatment of Trigeminal Neuralgia</brief_title>
  <official_title>A Randomized, Placebo-controlled Trial of Amifostine for Prevention of Facial Numbness in Patients Receiving Stereotactic Radiosurgery for Trigeminal Neuralgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trigeminal neuralgia or tic douloureux is severe, often debilitating, facial pain that
      significantly impairs the patient's quality of life and health. Stereotactic radiosurgery has
      been shown to provide pain relief in majority of patients treated. However, a common side
      effect of radiosurgery is facial numbness. Our goal is to maximize pain control while
      minimizing side effects. To this end, the purpose of this study is to evaluate whether adding
      a drug, amifostine, at the time of radiosurgery will protect patients from facial numbness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be evaluated by a multi-disciplinary team composed of radiation oncologists and
      neurosurgeons. Pretreatment pain, neurologic function (including facial numbness), and health
      related quality of life will be assessed. Patients will be treated in a single session with
      75 Gy maximal dose covering a 6 mm segment of the retrogasserian cisternal portion of the
      trigeminal sensory root. Treatment will be delivered using the CyberKnife Robotic
      Radiosurgery System with the patient in the supine position. An aquaplast head mask will be
      used to ensure adequate immobilization during therapy. The target volume shall be the 6 mm
      segment of the retrogasserian cisternal portion of the trigeminal sensory root. Patients will
      receive subcutaneous injection of amifostine (500 mg) or placebo 30 minutes +/- 30 minutes
      prior to SRS. Facial pain will be assessed using the Visual Analog Scale and Short-form
      McGill Pain Questionnaire. Following SRS, patients will be followed at 1, 3, 6, and 9 months
      Â±7 days. Facial numbness will be assessed using the Barrow Neurologic Institute (BNI) Facial
      Numbness Score. Patient reported BNI facial numbness scoring and complete cranial nerve exam
      by a physician will be performed pre-treatment and at follow-up visits.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Patterns of practice changed and this technique is no longer used.
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Facial Numbness Following Radiosurgery</measure>
    <time_frame>1 year</time_frame>
    <description>Percent of patients with facial numbness following radiosurgery will be determined at one year follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Relief Following Radiosurgery</measure>
    <time_frame>1 year</time_frame>
    <description>Pain improvement as assessed by the Barrow Neurological Institute (BNI) facial pain score from pre-treatment baseline of BNI 3-5 (3-some pain/controlled on medications, 4-some pain/not controlled on medications, 5-severe pain) to BNI 1-2 (1-no pain/ no medication, 2- occasional pain/no medication)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Trigeminal Neuralgia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and SRS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amifostine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amifostine and CyberKnife stereotactic radiosurgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amifostine</intervention_name>
    <description>Amifostine and CyberKnife stereotactic radiosurgery</description>
    <arm_group_label>Amifostine</arm_group_label>
    <other_name>CyberKnife stereotactic radiosurgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CyberKnife stereotactic radiosurgery</intervention_name>
    <description>CyberKnife stereotactic radiosurgery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All patients age 18 years and older with typical trigeminal neuralgia, as determined by
        diagnostic criteria set by the International Headache Society, who are:

          -  Intolerant of or refractory to medical management; AND

          -  Not candidates for or refusing a surgical micro-vascular decompression.

        Exclusion Criteria:

          -  Patients who present with pre-existing BNI grade III or IV facial numbness.

          -  Patients who have previously been treated with MVD.

          -  Patients who have previously had an ablative treatment, including prior SRS.

          -  Pediatric patients (age &lt;18), pregnant women, and patients who are unable to give
             informed consent will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clara Choi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott Soltys</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2011</study_first_submitted>
  <study_first_submitted_qc>June 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2011</study_first_posted>
  <results_first_submitted>December 16, 2016</results_first_submitted>
  <results_first_submitted_qc>February 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 4, 2017</results_first_posted>
  <last_update_submitted>February 16, 2017</last_update_submitted>
  <last_update_submitted_qc>February 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Scott Soltys</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>tic douloureux</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Trigeminal Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amifostine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients will be evaluated by a multi-disciplinary team composed of radiation oncologists and neurosurgeons. During their visit, a physician or research coordinator will explain the study. Patients will be given the informed consent form to read. If they agree to participate, they will be asked to sign the consent form prior to participating.</recruitment_details>
      <pre_assignment_details>Patientâs pretreatment pain, neurologic function (including facial numbness), and health related quality of life will be assessed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo and SRS
CyberKnife stereotactic radiosurgery (srs)</description>
        </group>
        <group group_id="P2">
          <title>Amifostine</title>
          <description>Amifostine and SRS
CyberKnife stereotactic radiosurgery and Amifostine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo and SRS
CyberKnife stereotactic radiosurgery + saline</description>
        </group>
        <group group_id="B2">
          <title>Amifostine</title>
          <description>Amifostine and CyberKnife stereotactic radiosurgery
CyberKnife stereotactic radiosurgery + amofostine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Facial Numbness Following Radiosurgery</title>
        <description>Percent of patients with facial numbness following radiosurgery will be determined at one year follow up.</description>
        <time_frame>1 year</time_frame>
        <population>One subject randomized to drug arm did not have data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo and SRS
CyberKnife stereotactic radiosurgery (srs)</description>
          </group>
          <group group_id="O2">
            <title>Amifostine</title>
            <description>Amifostine and SRS
CyberKnife stereotactic radiosurgery and Amifostine</description>
          </group>
        </group_list>
        <measure>
          <title>Facial Numbness Following Radiosurgery</title>
          <description>Percent of patients with facial numbness following radiosurgery will be determined at one year follow up.</description>
          <population>One subject randomized to drug arm did not have data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief Following Radiosurgery</title>
        <description>Pain improvement as assessed by the Barrow Neurological Institute (BNI) facial pain score from pre-treatment baseline of BNI 3-5 (3-some pain/controlled on medications, 4-some pain/not controlled on medications, 5-severe pain) to BNI 1-2 (1-no pain/ no medication, 2- occasional pain/no medication)</description>
        <time_frame>1 year</time_frame>
        <population>8 subjects were enrolled on the Amifostine arm, however, one subject was enrolled but withdrew prior to treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo and SRS
CyberKnife stereotactic radiosurgery (srs)</description>
          </group>
          <group group_id="O2">
            <title>Amifostine</title>
            <description>Amifostine and SRS
CyberKnife stereotactic radiosurgery and Amifostine</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief Following Radiosurgery</title>
          <description>Pain improvement as assessed by the Barrow Neurological Institute (BNI) facial pain score from pre-treatment baseline of BNI 3-5 (3-some pain/controlled on medications, 4-some pain/not controlled on medications, 5-severe pain) to BNI 1-2 (1-no pain/ no medication, 2- occasional pain/no medication)</description>
          <population>8 subjects were enrolled on the Amifostine arm, however, one subject was enrolled but withdrew prior to treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.175</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Our odds ratio is equal to 0*5/9*2 because we have a zero cell in the two by two table. Hence the OR = 0.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data was collected for 9 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo and SRS
CyberKnife stereotactic radiosurgery (srs)</description>
        </group>
        <group group_id="E2">
          <title>Amifostine</title>
          <description>Amifostine and SRS
CyberKnife stereotactic radiosurgery and Amifostine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Scott G. Soltys, Assistant Professor</name_or_title>
      <organization>Stanford University Cancer Center</organization>
      <phone>650.724.1569</phone>
      <email>sgsoltys@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

